Entry Detail


General Information

Database ID:exR0409513
RNA Name:hsa-miR-214-3p
RNA Type:miRNA
Chromosome:chr1
Starnd:-
Coordinate:
Start Site(bp):172138816End Site(bp):172138837
External Links:hsa-miR-214-3p



Disease Information

Disease Name:Osteoarthritis
Disease Category:Musculoskeletal Diseases
MeSH ID:D010003
Type:Diseases Category/Musculoskeletal Diseases
Alias:Osteoarthritides//Osteoarthrosis//Osteoarthroses//Arthritis, Degenerative//Arthritides, Degenerative//Degenerative Arthritides//Degenerative Arthritis//Arthrosis//Arthroses//Osteoarthrosis Deformans



Expression Detail

GEO ID:GSE126677
Description:miRNA sequencing of synovial fluid derived extracellular vesicles between normal and osteoarthritis (OA) patients
Experimental Design:Disease vs Control
Case Disease Type:Osteoarthritis
Case Disease SubType:NA
Case Sample:Osteoarthritis
Control Sample:Normal
Number of Case:2
Number of Control:3
Number of Samples:5





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
MTMR12
chr5
32226994
32312987
-
AP3M1
chr10
74120255
74151063
-
AMER1
chrX
64185117
64205708
-
GDI1
chrX
154436913
154443467
+
RPUSD1
chr16
784974
788397
-
SMG5
chr1
156249224
156282825
-
DHX36
chr3
154272546
154324487
-
PIP5K1C
chr19
3630183
3700479
-
C19orf47
chr19
40319536
40348527
-
MTMR3
chr22
29883155
30030866
+
ABHD2
chr15
89087459
89202355
+
MAPKAPK2
chr1
206684944
206734283
+
RHPN1
chr8
143368876
143384221
+
HDLBP
chr2
241227264
241317061
-
ARHGAP35
chr19
46860997
47005077
+
YWHAB
chr20
44885702
44908532
+
WDR5
chr9
134135365
134159968
+
RPS6KA1
chr1
26529761
26575030
+
JPT1
chr17
75135248
75168281
-
SEC61A1
chr3
128051641
128071683
+
TMEM161B
chr5
88189633
88269476
-
NECTIN1
chr11
119623408
119729200
-
SOX11
chr2
5692384
5701385
+
MYH9
chr22
36281277
36388067
-
RAB15
chr14
64945814
64973226
-
PLAGL2
chr20
32192504
32207743
-
TGIF2
chr20
36573488
36593950
+
NRIP1
chr21
14961235
15065936
-
LYSMD2
chr15
51723011
51751585
-
KMT2D
chr12
49018975
49059774
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000540
chr14
55799534
55821940
+
hsa_circ_0001168
chr20
47691321
47707559
+
hsa_circ_0001146
chr20
34241449
34246936
-
hsa_circ_0000799
chr17
65941524
65972074
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC008040.1
chr3
169939353
169966734
-
AC010442.1
chr5
466124
473098
-
AC016876.2
chr17
7581964
7584086
-
AC068790.9
chr12
124085761
124088598
+
AC109460.3
chr16
28974804
28990775
+
ADAMTSL4-AS1
chr1
150560202
150574552
-
AL031282.2
chr1
1702736
1737688
-
AL160006.1
chr1
110058340
110062555
+
EPB41L4A-AS1
chr5
112160526
112164818
+
FGD5-AS1
chr3
14920347
14948424
-
LINC00665
chr19
36313067
36331770
-
LINC01535
chr19
37251885
37265535
+
MIR17HG
chr13
91347820
91354579
+
NEAT1
chr11
65422774
65445540
+
POLR2J4
chr7
43940895
44019175
-
SNHG16
chr17
76557764
76565348
+
STAG3L5P-PVRIG2P-PILRB
chr7
100336104
100367831
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE126677
Sample Source:Synovial Fluid
Source Fraction:Extracellular Vesicle
Platform:GPL16791
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:539
Sample treatment protocol:NA
RNA Extract protocol:A small RNA was harvested from extracellular vesicles of human synovial fluids of normal and OA patients' joints using miRCURY RNA isolation kit for biofluids.
RNA library preparation protocol:A small RNA library was generated from a customer sample using the Illumina Truseq™ Small RNA Preparation kit according to Illumina's TruSeq™ Small RNA Sample Preparation Guide (Part # 15004197).



Reference

PMID:30944259
Title:Senescence cell-associated extracellular vesicles serve as osteoarthritis disease and therapeutic markers.
Author:Jeon OH, Wilson DR, Clement CC, Rathod S, Cherry C, Powell B, Lee Z, Khalil AM, Green JJ, Campisi J, Santambrogio L, Witwer KW, Elisseeff JH.
Journal:JCI Insight. 2019 Apr 4;4(7). pii: 125019.
Description:EV contents found in synovial fluid may serve as a diagnostic for arthritic disease and indicator for therapeutic efficacy of senolytic treatment.